Skip to main content
Equibles
BDSX logo

BDSX · Biodesix Inc

Track BDSX — free

Use BDSX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BDSX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$25.54 +3.20 (+14.32%) At close · Aug 19
Market Cap
$235.71M
Shares
10.55M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$25.54 Open$21.91 Day$21.91–26.40 Since split$5.46–25.54 Avg vol 30d80K Short int157K · 1.5% float · 2.7d Short vol27% Last earningsAug 5, 2026 DataSep 2025–Aug 2026 Filing10-Q · Aug 5

Raw chart and full-history price indicators begin at the captured split on Sep 15, 2025; bars on opposite sides are not compared.

The closing range begins at the captured split on Sep 15, 2025.

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +85%
      above
      Price vs 50-day avg +22%
      above
      RSI (14) 64
      neutral
      MACD trend Positive
      52-week position 100%
      near high
      Momentum
      relative strength
      Very Strong
      1-month return +19%
      trailing
      6-month return +80%
      trailing
      YTD return +276%
      this year
      Relative strength +68%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $21 › 200d $14 — 50d above 200d
      Institutional flow Accumulating
      +5% holders QoQ · +10 funds added
      Insider flow Accumulating
      Net +$1.0M over 90 days · 0% sells
      Short interest Falling
      1.49% of float · ▼ -6.4% MoM · 2.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      43 holders — mid 3-yr range
      Squeeze score 49
      elevated · 0–100
      Fundamentals
      Fair
      Revenue growth +24%
      Y/Y
      EPS growth +30%
      Y/Y
      Free cash flow $-23.5M
      Balance sheet $31.0M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 112%
      annualized · 1-yr
      Max drawdown −49%
      past year
      ATR 7.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 1 of last 2
      Latest guidance · from the Earnings Call filed Jun 30, 2026
      Full-year revenue · full-year 2026 $108M – $114M
      Prior guidance period ended · from the 8-K filed Nov 3, 2025
      Total revenue · 2025 $84M – $86M
      Guided vs delivered · last 2 settled
      Total revenue 2025
      guided $84M – $86M
      $88.5M Beat +4.1%
      Full year 2023 guidance full year 2023
      guided $50M – $52M
      $49.09M Miss −3.8%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 2 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +85% Bullish
      Price vs 50-day avg
      +22% Bullish
      RSI (14)
      64 Neutral
      MACD trend
      Positive Bullish
      52-week position
      100% Bullish
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $21 › 200d $14 — 50d above 200d
      Institutional flow Accumulating
      +5% holders QoQ · +10 funds added
      Insider flow Accumulating
      Net +$1.0M over 90 days · 0% sells
      Short interest Falling
      1.49% of float · ▼ -6.4% MoM · 2.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      43 holders — mid 3-yr range
      Price context
      position in its range since split · 2025-09-15
      Range low $5 Now $26 · 100% Range high $26
      vs 200-day avg +85% vs 50-day avg +22%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Gross margin 82% Q2 2026 —
      Diagnostic Tests core organic revenue, excluding collection on claims older than one year $24.1M the fourth quarter —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      BDSX
      Biodesix Inc
      this stock
      		$235.71M +275.6% +24.1% — 1.5%
      TMO
      Thermo Fisher Scientific Inc.
      		 $217.80B +5.9% +14.5% 31.7 1.3%
      DHR
      Danaher Corp /De/
      		 $147.41B -7.6% +8.5% 37.2 1.7%
      NTRA
      Natera, Inc.
      		 $45.29B +41.9% -2.8% — 3.0%
      IDXX
      Idexx Laboratories Inc /De
      		 $44.29B -16.9% +10.4% 39.5 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      43
      % held
      40.6%
      Net QoQ
      +370.7K sh
      Top holder
      AIGH Capital Management L…
      Held Float
      View
      Held by Funds
      Fund positions
      13
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      157.2K
      Days to cover
      2.7d
      Change
      -10.8K sh
      View
      Short Volume
      Short vol %
      27%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      13
      Value
      $290
      As of
      Jul 24, 2026
      View
      Off-Exchange
      Off-exchange %
      39.5%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$1.0M
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $88.5M
      Net income (FY)
      $-35.3M
      EPS diluted
      $-4.67
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 12, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $19.0K
      Shares
      1.5K
      Filed
      Feb 23, 2026
      View
      Exempt Offerings
      Offering
      $31.0M
      Filed
      Oct 1, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Sep 15, 2025; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      BDSX +5.5% +19.4% +79.6% +20.5% +275.6%
      SPY -0.4% +2.9% +11.6% +3.0% +12.8%
      vs SPY +5.9% +16.5% +68.0% +17.5% +262.8%
      Key facts CIK 1439725 CUSIP 09075X207 13F (30d) 42 filings 42 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)